Administrative Core

行政核心

• 批准号: 10747154
• 负责人: LONNY R LEVIN
• 金额: $ 25.12万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-10 至 2026-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10747154
• 关键词: Adenylate Cyclase; Advisory Committees; Affect; Animal Model; Biochemistry; Biological Availability; Biotechnology; Characteristics; Chemicals; Communication; Computer Models; Contraceptive Agents; Contraceptive methods; Crystallography; Data; Drug Kinetics; Elements; Ensure; Enzymatic Biochemistry; Evaluation; Fertilization; Fostering; Funding; Goals; Human; Human Resources; Infertility; Institution; Institutional Review Boards; Investigational New Drug Application; Lead; Link; Maintenance; Male Contraceptive Agents; Marketing; Medicine; Mus; National Institute of Child Health and Human Development; Oral; Oral Contraceptives; Partner in relationship; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacology; Physiology; Positioning Attribute; Principal Investigator; Property; Quality Control; Reproductive Biology; Research; Research Activity; Research Personnel; Resources; Series; Sperm Motility; Structure; Therapeutic; Time; Work; contraceptive efficacy; design; drug development; drug discovery; drug quality; early phase clinical trial; improved; in vivo; inhibitor; male; mating behavior; member; men; outreach; pharmacodynamic biomarker; pharmacologic; pill; preclinical development; preference; prevent; programs; recruit; scaffold; sperm cell; structural biology; tool

Administrative Core The objective of the Administrative Core is to link together the various elements of the Weill Cornell Medicine Contraception Research Center (WCM-CRC). This center, titled “On-demand nonhormonal male contraception via ADCY10 inhibition,” has a singular scientific theme; to identify the safest and most efficacious means for blocking soluble adenylyl cyclase (sAC; ADCY10) in vivo to achieve an on-demand contraceptive pill for men. To achieve this goal, the WCM-CRC leverages the established inter-disciplinary team comprised of expertise in sAC physiology, pharmacology, biochemistry, reproductive biology, structural biology, enzymology, computational modeling, medicinal chemistry, and drug development. This team, which has been effectively and efficiently working together for the past 4 years, successfully advanced sAC inhibitors into potent, specific, drug-like leads that demonstrated proof-of-concept for on- demand male contraception in vivo in mice. This administrative core mirrors the successful administrative core from the previously funded WCM-CRC; all personnel and operational resources are maintained. Due to the advancements made over the past four years, the WCM-CRC investigative team joined forces with an expert in reproductive biology and an expert in contraceptive marketing and end-user preferences to form Sacyl Pharmaceuticals, Inc. (SACYL), a biotech company established to further develop and market sAC inhibitors as nonhormonal, on-demand birth control pills for men. SACYL will provide `Pharma-quality' drug development expertise to augment the work proposed in this application. In addition to ensuring that the established group of collaborators comprising the WCM-CRC functions as a single entity, the WCM- CRC Administrative Core will be responsible for maintaining complementarity between the WCM-CRC and SACYL as well as fostering interactions between the WCM-CRC and NICHD program personnel, investigators in other CRCs, and regulatory agencies. The Core's administrative responsibilities include planning, flow of information, developing resources, outreach, and overall administration for the WCM- CRC. In practice, the WCM-CRC Administrative Core will provide structure and oversight for the already existing relationships between the two co-Principal Investigators, the other project leaders, SACYL, and the Center's advisory committees.

管理核心 行政核心的目标是将威尔康奈尔大学的各种要素联系在一起 药物避孕研究中心(WCM-CRC)。这个中心名为“按需非荷尔蒙男性” 通过抑制ADCY10进行避孕，“有一个独特的科学主题；找出最安全和最 阻断体内可溶性腺苷环化酶(SAC；ADCY10)的有效手段实现按需 男性避孕药。为了实现这一目标，WCM-CRC利用已建立的跨学科 团队由SAC生理学、药理学、生物化学、生殖生物学、 结构生物学、酶学、计算建模、药物化学和药物开发。这 团队，在过去的4年里，一直有效和高效地合作，成功地 先进的SAC抑制剂成为有效的、特定的、类药物的线索，证明了On-On的概念验证 要求在小鼠体内进行雄性避孕。此管理核心反映了成功的管理 核心来自以前资助的WCM-CRC；所有人员和业务资源都保持不变。到期 由于在过去四年中取得的进展，WCM-CRC调查小组与 生殖生物学专家和避孕药具营销和终端用户偏好专家 成立Sacyl制药公司(SACYL)，这是一家为进一步开发和营销而成立的生物技术公司 SAC抑制剂是男性非荷尔蒙的按需避孕药。共青团将提供‘医药质量’ 药物开发专业知识，以加强本申请中提议的工作。除了确保 组成WCM-CRC的已建立的协作者小组作为单个实体发挥作用，WCM- 《儿童权利公约行政核心》将负责维持《世界儿童权利公约》和《儿童权利公约》之间的互补性。 SACyl以及促进WCM-CRC和NICHD项目人员之间的互动， 其他CRC的调查人员和监管机构。核心部门的行政职责包括 WCM的规划、信息流、资源开发、推广和整体管理- CRC。在实践中，WCM-CRC行政核心将为已经 两名联合首席调查员、其他项目负责人、SACYL和 该中心的咨询委员会。